In vivo and in silico alpha-synuclein propagation dynamics: The role of genotype, epicentre, and connectivity

preprint OA: closed
📄 Open PDF Full text JSON View at publisher
Full text 1,960 characters · extracted from oa-doi-fallback · click to expand
Abstract Neurodegeneration observed in synucleinopathies, like Parkinson’s disease (PD), are hypothesized to be a consequence of the progressive accumulation and spread of misfolded alpha-synuclein (aSyn) throughout the brain. Here, we study the generalizability of this hypothesis across multiple biologically-relevant factors including genotype, aSyn species, and regional vulnerability (i.e.: does the introduction of aSyn into different brain regions have a similar impact) using a detailed longitudinal brain (using magnetic resonance imaging; [MRI]) and behavioural approaches. We first examined wild-type and M83 A53T hemizygous transgenic (engineered to over-express human aSyn) C57BL/6 x C3H mice receiving striatal inoculation with human or mouse preformed fibrils (PFFs) (n=89 mice at the last time point; n=687 MRI). Longitudinal analyses demonstrated a time-dependent increase in network-like atrophy and motor deficits, generalized across genotype and PFF species. We further derived latent dimensions relating brain-behaviour relationships revealing a pattern of sex- and genotype-relevant atrophy. Overall, atrophy was most prominent in M83 mice with mouse PFFs, while human PFFs or wild-type hosts showed attenuated effects. Changing the inoculation site to the hippocampus, a major connectivity hub, revealed differential regional vulnerability in the form of localized atrophy. Computational models previously validated in clinical PD further indicated regional vulnerability with increased predictive ability for atrophy patterns associated with striatal compared to hippocampal inoculation. Our findings reveal atrophy resulting from aSyn spreading is generalizable across genotype and PFF species, but not disease epicentres, emphasizing the role of regional vulnerability in disease progression. Competing Interest Statement The authors have declared no competing interest. Footnotes Funding information was added to the manuscript file.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00